Allogene Therapeutics, Inc.·4

Jan 28, 8:15 PM ET

Parker Geoffrey M. 4

4 · Allogene Therapeutics, Inc. · Filed Jan 28, 2025

Insider Transaction Report

Form 4
Period: 2025-01-24
Parker Geoffrey M.
CHIEF FINANCIAL OFFICER
Transactions
  • Award

    Common Stock

    2025-01-24+173,9131,305,901 total
  • Award

    Stock Option (Right to buy)

    2025-01-24+614,844614,844 total
    Exercise: $1.94Exp: 2035-01-24Common Stock (614,844 underlying)
Footnotes (1)
  • [F1]25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Documents

1 file
  • 4
    wk-form4_1738113304.xmlPrimary

    FORM 4